Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook

Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company (NYSE:LLY) on February 4, citing the pharmaceutical giant’s strong fiscal year 2026 projections. Eli Lilly & Company (NYSE:LLY) posted revenues of around $19.3 billion in the fourth quarter of 2025, exceeding Street projections of $18 billion, thanks mostly to strong results from its diabetes and obesity drugs Mounjaro and Zep ...